Medtronic has announced the launch of the Stedi Extra Support guidewire, designed to enhance stability during transcatheter aortic valve implantation (TAVI) valve deployment, particularly in conjunction with the company’s Evolut platform.
Compatible with all commercially available TAVI systems for patients with severe aortic stenosis, the Stedi guidewire combines a stiff proximal main body, gradual stiffness transition, and distal curve designed for stability, predictability, and safety, the company says in a press release.
“The Stedi Extra Support guidewire represents a meaningful advancement in TAVI,” said Tanvir J Bajwa (Advocate Health, Milwaukee, USA). “It enhances stability and predictability during valve deployment, especially when paired with techniques like simplified cusp overlap, and reinforces procedural consistency with the Evolut platform. This innovation supports more predictable outcomes and the precision we strive for in treating patients with severe aortic stenosis.”
Bench testing in a simulated anatomy has demonstrated that use of the Stedi guidewire, during deployment, when compared to less supportive wires with the Evolut platform, provides a reduction in ventricular movement, improved stability, and a more coaxial deployment, the company’s press release adds. Additionally, when used with the cusp overlap technique, extra support guidewires have been shown to be associated with a lower rate of permanent pacemaker implantation at 30 days.
“We continue to build a meaningful portfolio of procedural solutions which improve long-term outcomes for patients with aortic stenosis and advance the future of TAVI,” said Jorie Soskin, vice president and general manager of the Structural Heart business within the Cardiovascular Portfolio at Medtronic. “The Stedi guidewire is a complementary addition to our growing TAVI portfolio—purposefully designed to meet the evolving needs of physicians today and for the future, delivering enhanced stability and predictability while seamlessly integrating into existing Evolut workflows. Its thoughtful design supports procedural precision that can help drive improved patient-specific outcomes.”
The Stedi Extra Support guidewire has US Food and Drug Administration (FDA) clearance and is currently available in the USA. The device was launched at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference (25–28 October, San Francisco, USA).
